Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ENDV OTCMKTS:HCYTD OTCMKTS:LGMKD NASDAQ:PFSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENDVEndonovo Therapeutics$0.00$0.00$0.00▼$0.00N/A-1.03520,086 shs800,000 shsHCYTDH-CYTE$2.02-49.5%$2.02$2.02▼$77.00$521K1.12103 shs400 shsLGMKDLogicMark$1.00+75.4%$0.71$0.35▼$24.38$906K1.6762,721 shs610 shsPFSAProfusa$0.09$0.33$0.08▼$180.00$440K0.467.92 million shs6.92 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENDVEndonovo Therapeutics0.00%0.00%0.00%0.00%-50.00%HCYTDH-CYTE0.00%0.00%0.00%0.00%0.00%LGMKDLogicMark0.00%+69.78%+17.65%+132.56%-58.33%PFSAProfusa0.00%-18.27%-67.87%-87.66%+9,349,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENDVEndonovo Therapeutics$0.00$0.00$0.00▼$0.00N/A-1.03520,086 shs800,000 shsHCYTDH-CYTE$2.02-49.5%$2.02$2.02▼$77.00$521K1.12103 shs400 shsLGMKDLogicMark$1.00+75.4%$0.71$0.35▼$24.38$906K1.6762,721 shs610 shsPFSAProfusa$0.09$0.33$0.08▼$180.00$440K0.467.92 million shs6.92 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENDVEndonovo Therapeutics0.00%0.00%0.00%0.00%-50.00%HCYTDH-CYTE0.00%0.00%0.00%0.00%0.00%LGMKDLogicMark0.00%+69.78%+17.65%+132.56%-58.33%PFSAProfusa0.00%-18.27%-67.87%-87.66%+9,349,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENDVEndonovo Therapeutics 0.00N/AN/AN/AHCYTDH-CYTE 0.00N/AN/AN/ALGMKDLogicMark 2.00HoldN/AN/APFSAProfusa 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ENDV, HCYTD, LGMKD, and PFSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026PFSAProfusa Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENDVEndonovo Therapeutics$10K14.46N/AN/AN/A∞HCYTDH-CYTE$1.61M0.32N/AN/A($31.45) per share-0.06LGMKDLogicMark$9.90M0.09N/AN/A$19.33 per share0.05PFSAProfusa$100K4.36N/AN/A($21.69) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENDVEndonovo Therapeutics-$2.18MN/AN/AN/AN/AN/AN/AN/AN/AHCYTDH-CYTE-$4.80MN/AN/AN/AN/A-450.40%N/A-777.68%N/ALGMKDLogicMark-$9M-$94.52N/AN/AN/A-90.21%-57.08%-44.90%8/11/2026 (Estimated)PFSAProfusa-$35.82M-$169.72N/AN/AN/AN/AN/A-1,348.07%N/ALatest ENDV, HCYTD, LGMKD, and PFSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PFSAProfusaN/A-$2.05N/A-$2.05N/AN/A4/15/2026Q4 2025PFSAProfusaN/A$89.25N/A$89.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENDVEndonovo TherapeuticsN/AN/AN/AN/AN/AHCYTDH-CYTEN/AN/AN/AN/AN/ALGMKDLogicMarkN/AN/AN/AN/AN/APFSAProfusaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENDVEndonovo TherapeuticsN/AN/AN/AHCYTDH-CYTEN/A0.120.12LGMKDLogicMarkN/A5.625.18PFSAProfusaN/A0.020.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENDVEndonovo TherapeuticsN/AHCYTDH-CYTEN/ALGMKDLogicMark7.88%PFSAProfusa9.81%Insider OwnershipCompanyInsider OwnershipENDVEndonovo Therapeutics5.61%HCYTDH-CYTE5.24%LGMKDLogicMark2.17%PFSAProfusa0.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENDVEndonovo Therapeutics11.45 billion1.36 billionNot OptionableHCYTDH-CYTE8258,000244,000Not OptionableLGMKDLogicMark20906,000886,000No DataPFSAProfusa24.66 million4.63 millionN/AENDV, HCYTD, LGMKD, and PFSA HeadlinesRecent News About These CompaniesThis biotech stock crashed 28% today after announcing second reverse share split this yearJuly 2 at 6:07 PM | msn.comProfusa Announces 1-for-25 Reverse Stock Split Effective July 7, 2026July 2 at 11:11 AM | quiverquant.comQProfusa Announces 1-for-25 Reverse Stock SplitJuly 2 at 11:00 AM | globenewswire.comProfusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance EffortsJune 24, 2026 | globenewswire.comProfusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen PlatformJune 12, 2026 | globenewswire.comProfusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual MeetingJune 10, 2026 | globenewswire.comProfusa Taps Equity Line With Dilutive True-Up MechanismJune 8, 2026 | tipranks.comProfusa Taps Equity Line for Near-Term LiquidityMay 18, 2026 | tipranks.comProfusa Transfers Nasdaq Listing Amid Ongoing Compliance UncertaintyMay 17, 2026 | theglobeandmail.comProfusa Announces Listing Transfer to The Nasdaq Capital MarketMay 15, 2026 | markets.businessinsider.comProfusa Announces Listing Transfer to The Nasdaq Capital MarketMay 15, 2026 | globenewswire.comProfusa Granted Conditional Nasdaq Listing Extension and TransferMay 8, 2026 | tipranks.comProfusa, Inc. Granted Transfer to Nasdaq Capital Market Amid Compliance EffortsMay 8, 2026 | quiverquant.comQProfusa Receives Favorable Nasdaq Listing DeterminationMay 8, 2026 | globenewswire.comProfusa, Inc.: Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder ValueMay 5, 2026 | finanznachrichten.deProfusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder ValueMay 5, 2026 | globenewswire.comWhat's going on with Profusa stock Tuesday?April 7, 2026 | msn.comProfusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of ...April 6, 2026 | caledonianrecord.comCProfusa, Inc.: Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics PlatformApril 6, 2026 | finanznachrichten.deProfusa (PFSA) Stock Soars 173% on $30M PanOmics Diagnostics AcquisitionApril 6, 2026 | blockonomi.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENDV, HCYTD, LGMKD, and PFSA Company DescriptionsEndonovo Therapeutics OTCMKTS:ENDV$0.0001 0.00 (0.00%) As of 07/2/2026 02:52 PM EasternEndonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.H-CYTE OTCMKTS:HCYTD$2.02 -1.98 (-49.50%) As of 07/11/2022H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.LogicMark OTCMKTS:LGMKD$1.00 +0.43 (+75.44%) As of 07/2/2026LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company's devices provide people with the ability to receive care at home and age independently and to check, manage, and monitor a loved one's health and safety remotely. It also manufactures and distributes non-monitored and monitored personal emergency response systems, which are offered through the United States Veterans Health Administration (VHA), direct-to-consumers, healthcare durable medical equipment dealers and distributors, monitored security dealers and distributors, and its ecommerce website logicmark.com and Amazon.com. The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022. LogicMark, Inc. was founded in 2006 and is based in Louisville, Kentucky.Profusa NASDAQ:PFSA$0.09 0.00 (0.00%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$0.09 0.00 (-5.13%) As of 07/2/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
